Introduction
Despite advances in perinatal care, serious morbidity among small preterm infants still necessiates pronged, expensive neonatal care. While an increased number of infants with respiratory distress syndrome (RDS) survive, a considerable proportion of them may develop chronic debilitating disease, known as bronchopulmonary dysplasia (BPD) [18, 21] . Thus, a prevention of the long term morbidity among the small preterm infants with lung immaturity is a great challenge. Since lack of surfactant is the main cause of RDS, surfactant supplementation could be an effective method to prevent the morbidity associated with immaturity. Natural surfactant, applied to immature animal lung causes a striking acute improvement in respiratory function [1, 11, 12] , whereas the synthetic surfactant preparations have had modest acute effects, if any. Following the report of FUJIWARA [4] , natural surfactant has been mainly used in clinical trials. Non-randomized studies have demonstrated that surfactant substitution acutely improves the oxygenation and decreases the respiratory support [3, 4, 9, 24] . Only well-designed, randomized studies can evaluate objectively the ri$ks and benefits of surfactant supplementation.
Natural surfactant
Composition: "Natural" surfactant consists of unique proteins [14] and lipids [6] . Surfactant is considered to be "natural" when its principal components are derived from the lung. Extensive investigation is required to establish a "new" surfactant to be used in therapy [20] . Table I [22] and it is a structural component of the tubular myelin [26] . All natural surfactants contain low molecular weight proteolipid(s). The small molecular weight surfactant proteolipids (5 -18 kDalton) enhance greatly the surface adsoprtion of phospholipids, thereby allowing saturated phosphatidylcholine to concentrate on interphases and eliminate the surface forces. Liposomes containing synthetic phospholipids and the surfactant proteolipid may approach the activity of the natural surfactant in stabilizing the alveoli of surfactant deficient lungs. Besides the biochemical composition, the biophysical micellar form is another issue that influences the biological activity. Many surfactants, including that from human amniotic fluid, consist mainly of multilamellar structures. Availability: Heterologous surfactant from animal lungs may become available for treatment of RDS. Human surfactant may be harvested from amniotic fluid and distrivuted from "surfactant banks" for treatment of RDS (figure 1). Human surfactant should be the model for the "natural" surfactant produced by available biomedical techniques in unlimited quantities. Administration and dosage: According to current practice, surfactant is introduced through an endotracheal tube as a bolus of 3 to 5 ml using a saline vehicle to small preterm infants (table I) . In preterm lambs at birth a bolus of 60 mg/kg resulted in maximal acute improvement in respiratory failure [11] . A similar dose, given in RDS to small preterm infants permanently improved the respiratory function only in 50% of the cases, whereas in the others the response was unsatisfactory or it vanished resulting in a relapse of respiratory failure [7] . Exogenous surfactant decreased concomitant with the relapse [8] . Altogether 22 out of 31 of immature small preterm infants receiving 60 mg human surfactant within ten minutes of birth required retreatment because of (mostly mild) respiratory failure [17] . Most infants responded favorably to retreatment (figure 2), whereas in 8% of the infants the alleviation of the respiratory failure was transient despite retreatment. Although the exogenous surfactant disap-^ peared from the airways with a half life of 30 (range 20 -36) hours there was no relapse of respiratory failure since the amount of endogenous surfactant in the airways increased [8] . The occasional therapeutic failure can be due to surfactant inhibitors or exceptionally rapid disappearance of exogenous surfactant from the airways. Furthermore, exogenous surfactant does not distribute evenly in peripheral airways in severe lung injury [13] .
According to animal studies prophylactic surfactant at birth is more efficacious than surfactant given in respiratory failure [12] . The superiority of "prophylactic" to "rescue" surfactant has not yet been demonstrated in a concurrent clinical trial. Table II lists the present 3 randomized clinical trials thus far. Many others α are underway. The infants, who were given bovine t3 surfactant before the first breath had a lower < § incidence of RDS than the controls who were ĝ iven air [2] . It is unclear, whether bovine surfac-°t ant actually prevented RDS, since the degree of ; § biochemical lung maturity was not studied. & 'S Side effects: The dramatic improvement in gas ·| exchange could be envisioned as having undesir-jo able circulatory consequences. FUJIWARA ob-g served cardiorespiratory failure due to left to right & shunting through the patent ductus arteriosus B (PDA) following bovine surfactant [3, 4] . Others 3 did not find an increased incidence or severity of & •H " Ί l, ί H PDA shunting [2, 7, 17] . Indomethacin prior to surfactant did not improve the remission of the respiratory failure [5] . Indeed, the ductus arteriosus may constrict shortly after exogenous surfactant administration. The left to right shunt through PDA needs to be closely surveyed and promptly treated, since the limited reserve of the left ventricle could result in severe cardiac failure, pulmonary edema, and proteinacecous inhibitors "leaking" into the airspaces.
Some patients have demonstrated a transient decrease in the blood pressure following surfactant instillation. This phenomenon may be due to acute vasodilatation, possibly as a result of an oxygeninduced increase in prostacyclin and a decrease in platelet-derived tromboxane (unpublished results). The risk can be eliminated by infusing blood volume expanders before surfactant.
Present evidence suggests that exogenous surfactant does not inhibit the endogenous secretion. Instead, it could provide substates for a rate limiting step in endogenous surfactant synthesis, and stimulate the secretion of endogenous surfactant [8] .
Surfactant could conceivably be antigenic when administered intratracheally, thus raising concerns about the potential for sensitization or imrnunologic injury on infants so treated. STRAYER et al. demonstrated a transient increase in surfactantanti-surfactant immunocomplex formation in RDS regardless whether they had received exogenous human surfactant. This observation suggests that in RDS surfactant gains access to the systemic circulation; however, there was no evidence of immunocomplex-related disease detectable by clinical or by serologic means [25] . No antibodies against exogenous animal surfactant were detected in six survivors with RDS [19] . This issue is still unsettled because of lack of adequate studies.
Antibody formation against surfactant proteins must be rigorously excluded prior to suggesting the safety of heterologous surfactant.
A drug may contain microbes or toxins. All natural surfactants used in clinical trials are reportedly free from bacteria, fungi or even viruses. Today, our human surfactant undergoes heat treatment to eliminate HI virus. No toxic reactions, including pyrogen reactions, have thus far been reported although continuous surveillance is required.
Does surfactant improve the outcome of small preterm infants? Randomized trials in small preterm infants have demonstrated that surfactant substitution decreases the occurrence of acute complications, pulmonary interstitial emphysema and Pneumothorax (table II) . There has been no detectable (i.e. more than 50%) decrease in the incidence of intraventricular hemorrhage or PDA, whereas the incidence of death and BPD decreased following human surfactant (table II) . Thus far, there are neither published cost benefit analyses nor follow up data.
Possible indications of exogenous surfactant: RDS
is a spectrum of diseases involving infants with various degrees of "immaturity" and other abnormalities [6] . In adult respiratory distress syndrome serious surfactant defects are virtually always present, too [10] . Exogenous surfactant has a favorable response in respiratory failure in animals, regardless of the etiology [16] . Therefore, the indications of surfactant therapy can be wider than expected merely on the basis of the trials published at present. It is hoped that the more general availability of surfactant for therapeutic purposes does not result in injudicious practise but instead stimulates research on a wide variety of issues that eventually maximize the benefits and minimize the side effects of this potent therapy. 
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